• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Respiratory syncytial virus seasonality and its implications on prevention strategies.呼吸道合胞病毒的季节性及其对预防策略的影响。
Hum Vaccin Immunother. 2018 Jan 2;14(1):234-244. doi: 10.1080/21645515.2017.1403707. Epub 2017 Dec 15.
2
Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.呼吸道合胞病毒的季节性和低收入及中等收入国家婴儿被动免疫预防策略规划:建模研究。
Lancet Infect Dis. 2021 Sep;21(9):1303-1312. doi: 10.1016/S1473-3099(20)30703-9. Epub 2021 May 6.
3
Respiratory syncytial virus seasonality, transmission zones, and implications for seasonal prevention strategy in China: a systematic analysis.呼吸道合胞病毒的季节性、传播区域及其对中国季节性预防策略的影响:系统分析。
Lancet Glob Health. 2024 Jun;12(6):e1005-e1016. doi: 10.1016/S2214-109X(24)00090-1. Epub 2024 Apr 23.
4
Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.在高收入环境下,对一种针对母亲的呼吸道合胞病毒(RSV)疫苗的家庭层面影响进行建模。
BMC Med. 2020 Nov 12;18(1):319. doi: 10.1186/s12916-020-01783-8.
5
Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.评估呼吸道合胞病毒(RSV)主动免疫的效果:系统评价,重点关注疫苗接种策略、建模方法和输入数据。
Pharmacoeconomics. 2021 Mar;39(3):287-315. doi: 10.1007/s40273-020-00991-7. Epub 2021 Jan 19.
6
Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?婴儿呼吸道合胞病毒:母体疫苗接种是一种现实的策略吗?
Curr Opin Infect Dis. 2015 Jun;28(3):221-4. doi: 10.1097/QCO.0000000000000161.
7
Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.作为呼吸道合胞病毒的母体疫苗的替代病毒样颗粒相关前融合 F 蛋白。
J Virol. 2019 Nov 13;93(23). doi: 10.1128/JVI.00914-19. Print 2019 Dec 1.
8
Advances in and the potential of vaccines for respiratory syncytial virus.呼吸道合胞病毒疫苗的进展和潜力。
Expert Rev Respir Med. 2013 Aug;7(4):411-27. doi: 10.1586/17476348.2013.814409.
9
Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.在肯尼亚基利菲区对从出生起观察到的婴幼儿呼吸道合胞病毒感染及疾病情况。
Clin Infect Dis. 2008 Jan 1;46(1):50-7. doi: 10.1086/524019.
10
Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.加拿大孕33至35足周出生的早产儿呼吸道合胞病毒预防风险评分工具。
Curr Med Res Opin. 2009 Jul;25(7):1585-91. doi: 10.1185/03007990902929112.

引用本文的文献

1
Addressing the Underestimated Burden of RSV in Older Adults in Europe: Epidemiology, Surveillance Gaps, and Public Health Implications.应对欧洲老年人中被低估的呼吸道合胞病毒负担:流行病学、监测差距及对公共卫生的影响
Vaccines (Basel). 2025 May 12;13(5):510. doi: 10.3390/vaccines13050510.
2
Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus.疫苗接种的最佳时机:关于新冠病毒、流感和呼吸道合胞病毒综合策略的叙述性综述
Infect Dis Ther. 2025 May;14(5):911-932. doi: 10.1007/s40121-025-01135-0. Epub 2025 Apr 10.
3
Prevention of respiratory syncytial virus disease across the lifespan in Italy.意大利全生命周期呼吸道合胞病毒疾病的预防
Pneumonia (Nathan). 2025 Apr 5;17(1):8. doi: 10.1186/s41479-025-00160-4.
4
Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy.意大利呼吸道合胞病毒相关的经济和临床负担以及尼塞韦单抗通用免疫的影响
Glob Reg Health Technol Assess. 2025 Jan 29;12:16-28. doi: 10.33393/grhta.2025.3182. eCollection 2025 Jan-Dec.
5
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.呼吸道合胞病毒:关于新预防方案的瓦迪德共识文件
Vaccines (Basel). 2024 Nov 25;12(12):1317. doi: 10.3390/vaccines12121317.
6
Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative Review.流感病毒、呼吸道合胞病毒和严重急性呼吸综合征冠状病毒2引起的急性呼吸道感染负担:一项纳入老年人的叙述性综述
Infect Dis Ther. 2025 Jan;14(Suppl 1):5-37. doi: 10.1007/s40121-024-01080-4. Epub 2024 Dec 30.
7
Variability in the Timing of Respiratory Syncytial Virus Epidemics in Guatemala, 2008-2018. Guatemalteca. 2008-2018.
Influenza Other Respir Viruses. 2024 Jul;18(7):e13334. doi: 10.1111/irv.13334.
8
Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures.呼吸道合胞病毒A亚组和B亚组之间的差异及其对药物预防措施的影响。
Infect Dis Ther. 2024 Aug;13(8):1725-1742. doi: 10.1007/s40121-024-01012-2. Epub 2024 Jul 6.
9
RSV Infection in Refugees and Asylum Seekers: A Systematic Review and Meta-Analysis.难民和寻求庇护者中的呼吸道合胞病毒感染:系统评价与荟萃分析
Epidemiologia (Basel). 2024 May 27;5(2):221-249. doi: 10.3390/epidemiologia5020016.
10
Trends in hospitalizations of children with respiratory syncytial virus aged less than 1 year in Italy, from 2015 to 2019.意大利 2015 至 2019 年小于 1 岁因呼吸道合胞病毒住院的儿童趋势。
Ital J Pediatr. 2024 Jun 21;50(1):119. doi: 10.1186/s13052-024-01688-9.

本文引用的文献

1
Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.评估帕利珠单抗预防早产儿呼吸道合胞病毒感染的成本差异。
Pharmacoecon Open. 2018 Mar;2(1):53-61. doi: 10.1007/s41669-017-0042-3.
2
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.美国早产和足月婴儿因呼吸道合胞病毒住院时的年龄。
Infect Dis Ther. 2017 Dec;6(4):477-486. doi: 10.1007/s40121-017-0167-9. Epub 2017 Sep 2.
3
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England.小儿呼吸道合胞病毒疾病负担及不同免疫策略的潜在影响:英格兰的建模与成本效益分析
Lancet Public Health. 2017 Jul 31;2(8):e367-e374. doi: 10.1016/S2468-2667(17)30103-2. eCollection 2017 Aug.
4
Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012.估算2007 - 2012年呼吸道合胞病毒(RSV)对英格兰5岁以下儿童因呼吸道疾病住院治疗的负担。
Influenza Other Respir Viruses. 2017 Mar;11(2):122-129. doi: 10.1111/irv.12443. Epub 2017 Jan 21.
5
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.MEDI8897(一种半衰期延长的呼吸道合胞病毒前融合F靶向单克隆抗体)在健康成人中的安全性、耐受性和药代动力学。
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01714-16. Print 2017 Mar.
6
Vaccination strategies against respiratory syncytial virus.针对呼吸道合胞病毒的疫苗接种策略。
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13239-13244. doi: 10.1073/pnas.1522597113. Epub 2016 Oct 31.
7
Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization: Secondary Analysis of a Randomized Clinical Trial.母亲免疫接种为婴儿提供的流感疾病保护持续时间:一项随机临床试验的二次分析。
JAMA Pediatr. 2016 Sep 1;170(9):840-7. doi: 10.1001/jamapediatrics.2016.0921.
8
Time series analysis of RSV and bronchiolitis seasonality in temperate and tropical Western Australia.西澳大利亚温带和热带地区呼吸道合胞病毒(RSV)与细支气管炎季节性的时间序列分析
Epidemics. 2016 Sep;16:49-55. doi: 10.1016/j.epidem.2016.05.001. Epub 2016 May 25.
9
Advances in RSV vaccine research and development - A global agenda.呼吸道合胞病毒疫苗研发进展——一项全球议程。
Vaccine. 2016 Jun 3;34(26):2870-2875. doi: 10.1016/j.vaccine.2016.03.109. Epub 2016 Apr 19.
10
Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy.妊娠期呼吸道合胞病毒感染的临床表现及分娩结局
PLoS One. 2016 Mar 31;11(3):e0152015. doi: 10.1371/journal.pone.0152015. eCollection 2016.

呼吸道合胞病毒的季节性及其对预防策略的影响。

Respiratory syncytial virus seasonality and its implications on prevention strategies.

机构信息

a Oxford Vaccine Group, Department of Paediatrics , University of Oxford and the NIHR Oxford Biomedical Research Centre , Oxford , UK.

出版信息

Hum Vaccin Immunother. 2018 Jan 2;14(1):234-244. doi: 10.1080/21645515.2017.1403707. Epub 2017 Dec 15.

DOI:10.1080/21645515.2017.1403707
PMID:29194014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5791579/
Abstract

With maternal and infant vaccines against respiratory syncytial virus (RSV) in development, it is timely to consider how the deployment of these vaccines might vary according to local RSV disease seasonality. In temperate regions RSV infection is predictably limited to a period of 3 to 5 months, while in tropical regions disease seasonality is often both more variable and more prolonged. Accordingly, in tropical regions a year-round immunisation schedule for both maternal and infant immunisation might be appropriate. In contrast, in temperate regions the benefit of year-round maternal immunisation would be heavily dependent on the duration of protection this provided, potentially necessitating a strategy directed at children due to be born in the months immediately prior to the RSV season. This review will consider the impact of seasonality on maternal and infant immunisation strategies against RSV, and the potential of an alternative approach of passive immunisation for all infants immediately prior to the RSV season.

摘要

随着针对呼吸道合胞病毒(RSV)的母婴疫苗的研发,现在正是考虑这些疫苗的部署方式可能会根据当地 RSV 疾病季节性而有所不同的时候。在温带地区,RSV 感染可预测地局限于 3 至 5 个月的时间段,而在热带地区,疾病季节性往往更加多变且持续时间更长。因此,在热带地区,针对母婴的全年免疫接种计划可能是合适的。相比之下,在温带地区,全年进行母婴免疫接种的益处将在很大程度上取决于这种免疫接种提供的保护持续时间,这可能需要针对即将在 RSV 季节前几个月出生的儿童采取一种策略。这篇综述将考虑季节性对 RSV 母婴免疫策略的影响,以及在 RSV 季节前为所有婴儿提供被动免疫的替代方法的潜力。